Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senomyx, Solae savory soy

This article was originally published in The Tan Sheet

Executive Summary

A partnership by soy protein supplier Solae and flavor technology developer Senomyx aims to improve soy protein's taste through the development of bitter blockers. Since April 2007, scientists from both firms have collaborated to determine the bitter components of soy protein and discovered new ingredients to modulate how taste receptors respond, the companies say Sept. 15. Under a licensing agreement, Solae will retain exclusive worldwide rights to use the soy protein flavor ingredients in all food and beverages, with Senomyx receiving royalties based on sales. San Diego-based Senomyx previously sought bitter-blocking agents for use in OTC pediatric products (1"The Tan Sheet" Jan. 16, 2006, p. 13). St. Louis-based Solae once pursued a qualified health claim linking soy protein to cancer prevention, but withdrew its petition in 2005 (2"The Tan Sheet" Oct. 31, 2005, In Brief)

Related Content

Topics

UsernamePublicRestriction

Register

PS102178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel